<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35925071</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2731-7099</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Innere Medizin (Heidelberg, Germany)</Title><ISOAbbreviation>Inn Med (Heidelb)</ISOAbbreviation></Journal><ArticleTitle>[Frequency, spectrum and risk factors of long COVID].</ArticleTitle><Pagination><StartPage>813</StartPage><EndPage>818</EndPage><MedlinePgn>813-818</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00108-022-01370-4</ELocationID><Abstract><AbstractText>Between 10 and 20% of individuals infected with severe acute respiratory syndrome coronavirus type&#xa0;2 (SARS-CoV-2) suffer from symptoms up to weeks after initial infection. The most frequently reported symptoms include fatigue, dyspnea, anosmia and ageusia, as well as headaches, joint pain, cough, cognitive impairment and impaired sleeping. After exclusion of other etiologies and symptom duration of more than 4&#xa0;weeks after initial infection this is referred to as long COVID. In contrast to acute coronavirus disease 2019 (COVID-19), no specific risk factors have been identified as yet as being associated with the occurrence of this disease. Furthermore, there are varying hypotheses concerning the pathomechanism of long COVID. Dividing patients into groups is beneficial in the clinical context. Regardless of long COVID symptoms the risk of cardiovascular events is increased even 1&#xa0;year after COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pink</LastName><ForeName>Isabell</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Pneumologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str.&#xa0;1, 30625, Hannover, Deutschland. pink.isabell@mh-hannover.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welte</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Pneumologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str.&#xa0;1, 30625, Hannover, Deutschland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>H&#xe4;ufigkeit, Spektrum und Risikofaktoren von Long-COVID.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Inn Med (Heidelb)</MedlineTA><NlmUniqueID>9918384885306676</NlmUniqueID><ISSNLinking>2731-7080</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000370" MajorTopicYN="Y">Ageusia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Bei 10&#x2013;20&#x202f;% aller Menschen, die sich mit &#x201e;severe acute respiratory syndrome coronavirus type&#xa0;2&#x201c; (SARS-CoV-2) infiziert haben, bleiben auch Wochen nach der Infektion noch Beschwerden zur&#xfc;ck. Meist klagen die Betroffenen &#xfc;ber Fatigue, Dyspnoe, Anosmie und Ageusie, zudem &#xfc;ber Kopfschmerzen, Gelenkschmerzen, Husten, kognitive Einschr&#xe4;nkungen und Schlafst&#xf6;rungen. Scheiden andere Ursachen aus und bestehen die Beschwerden l&#xe4;nger als 4&#xa0;Wochen, wird dies meist als Long-COVID bezeichnet. Anders als bei der akuten &#x201e;coronavirus disease 2019&#x201c; (COVID-19), konnten bisher keine sicheren Risikofaktoren identifiziert werden, die mit dem Auftreten der Erkrankung assoziiert sind. Auch in Bezug auf die Pathogenese gibt es mehrere Hypothesen. Klinisch hilft eine Einteilung der Patient*innen in Gruppen. Unabh&#xe4;ngig von Beschwerden im Rahmen von Long-COVID ist das Risiko kardiovaskul&#xe4;rer Ereignisse auch ein Jahr nach COVID-19 erh&#xf6;ht.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular complications</Keyword><Keyword MajorTopicYN="N">Dyspnea</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Post-covid-19-syndrom</Keyword><Keyword MajorTopicYN="N">Severe acute respiratory syndrome coronavirus type&#xa0;2 (SARS-CoV-2)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35925071</ArticleId><ArticleId IdType="pmc">PMC9261882</ArticleId><ArticleId IdType="doi">10.1007/s00108-022-01370-4</ArticleId><ArticleId IdType="pii">10.1007/s00108-022-01370-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022 doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniou KM, Vasarmidi E, Russell A-M, et al. European respiratory society statement on long COVID-19 follow-up. Eur Respir J. 2022 doi: 10.1183/13993003.02174-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02174-2021</ArticleId><ArticleId IdType="pmc">PMC9349784</ArticleId><ArticleId IdType="pubmed">35144991</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a&#xa0;longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2021;147:545&#x2013;557.e9. doi: 10.1016/j.jaci.2020.10.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.10.040</ArticleId><ArticleId IdType="pmc">PMC7677074</ArticleId><ArticleId IdType="pubmed">33221383</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13:446. doi: 10.1038/s41467-021-27797-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, et al. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021 doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhaeze T, Tremblay L, Lachance C, et al. CD70 defines a&#xa0;subset of proinflammatory and CNS-pathogenic TH1/TH17 lymphocytes and is overexpressed in multiple sclerosis. Cell Mol Immunol. 2019;16:652&#x2013;665. doi: 10.1038/s41423-018-0198-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-018-0198-5</ArticleId><ArticleId IdType="pmc">PMC6804668</ArticleId><ArticleId IdType="pubmed">30635649</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020 doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-coV-2 infection: a systematic review. JAMA Netw Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26:1017&#x2013;1032. doi: 10.1038/s41591-020-0968-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0968-3</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, et al. Health outcomes in people 2&#xa0;years after surviving hospitalisation with COVID-19: a&#xa0;longitudinal cohort study. Lancet Respir Med. 2022 doi: 10.1016/S2213-2600(22)00126-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue S, Hatakeyama J, Kondo Y, et al. Post-intensive care syndrome: its pathophysiology, prevention, and future directions. Acute Med Surg. 2019;6:233&#x2013;246. doi: 10.1002/ams2.415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ams2.415</ArticleId><ArticleId IdType="pmc">PMC6603316</ArticleId><ArticleId IdType="pubmed">31304024</ArticleId></ArticleIdList></Reference><Reference><Citation>Koczulla AR, Ankermann T, Behrends U, et al. S1-Leitlinie Post-COVID/Long-COVID. Pneumologie. 2021 doi: 10.1055/a-1551-9734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1551-9734</ArticleId><ArticleId IdType="pubmed">34474488</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques KC, Silva CC, da Trindade SS, et al. Reduction of cardiac autonomic modulation and increased sympathetic activity by heart rate variability in patients with long COVID. Front Cardiovasc Med. 2022;9:862001. doi: 10.3389/fcvm.2022.862001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.862001</ArticleId><ArticleId IdType="pmc">PMC9098798</ArticleId><ArticleId IdType="pubmed">35571200</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O, Merino E, Leon-Ramirez J-M, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a mediterranean cohort study. J Infect. 2021;82:378&#x2013;383. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>PHOSP-COVID Collaborative Group Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a&#xa0;prospective observational study. Lancet Respir Med. 2022 doi: 10.1016/S2213-2600(22)00127-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical&#x2013;therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405&#x2013;407. doi: 10.1016/j.healun.2020.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2020.03.012</ArticleId><ArticleId IdType="pmc">PMC7118652</ArticleId><ArticleId IdType="pubmed">32362390</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Taylor S. NICE guideline on long covid. BMJ. 2020 doi: 10.1136/bmj.m4938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4938</ArticleId><ArticleId IdType="pubmed">33361141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Welte T. Post-COVID syndrome&#x2014;more questions than answers. Dtsch Arztebl Int. 2022 doi: 10.3238/arztebl.m2022.0154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.m2022.0154</ArticleId><ArticleId IdType="pmc">PMC9215270</ArticleId><ArticleId IdType="pubmed">35583038</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation> A clinical case definition of post COVID-19 condition by a&#xa0;Delphi consensus. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (Erstellt: 6. Okt. 2021). Zugegriffen: 2. Nov. 2021</Citation></Reference><Reference><Citation> Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK&#x2014;Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/6may2022. Zugegriffen: 28. Mai 2022</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>